Merck & Co., Inc. Deferred Tax Liabilities, Intangible Assets
Merck & Co., Inc. (MRK) had Deferred Tax Liabilities, Intangible Assets of $3.27 billion as of 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Liabilities, Gross
us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets · last filed 2026-02-24
- 2025-12-31: Deferred Tax Liabilities, Intangible Assets $3.27B.
- 2024-12-31: Deferred Tax Liabilities, Intangible Assets $978.00M.
- 2023-12-31: Deferred Tax Liabilities, Intangible Assets $1.31B.
- 2022-12-31: Deferred Tax Liabilities, Intangible Assets $2.58B.
| Period end | Deferred Tax Liabilities, Intangible Assets | Deferred Tax Liabilities, Intangible Assets as first filed |
|---|---|---|
| 2025-12-31 | $3.27B 10-K · filed 2026-02-24 | |
| 2024-12-31 | $978.00M 10-K · filed 2026-02-24 | |
| 2023-12-31 | $1.31B 10-K · filed 2025-02-25 | |
| 2022-12-31 | $2.58B 10-K · filed 2024-02-26 | |
| 2021-12-31 | $3.21B 10-K · filed 2023-02-24 | $2.93B 10-K · filed 2022-02-25 |
| 2020-12-31 | $1.25B 10-K · filed 2022-02-25 | |
| 2019-12-31 | $1.78B 10-K · filed 2021-02-25 | |
| 2018-12-31 | $1.64B 10-K · filed 2020-02-26 | |
| 2017-12-31 | $2.26B 10-K · filed 2019-02-27 | $2.44B 10-K · filed 2018-02-27 |
| 2016-12-31 | $3.85B 10-K · filed 2018-02-27 | $3.73B 10-K · filed 2017-02-28 |
| 2015-12-31 | $4.96B 10-K · filed 2017-02-28 | |
| 2014-12-31 | $3.36B 10-K · filed 2016-02-26 | |
| 2013-12-31 | $3.77B 10-K · filed 2015-02-27 | |
| 2012-12-31 | $4.58B 10-K · filed 2014-02-27 | |
| 2011-12-31 | $5.33B 10-K · filed 2013-02-28 | |
| 2010-12-31 | $6.67B 10-K · filed 2012-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |